Medication info
Janumix Tablet 50/850 mg

Janumix Tablet 50/850 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Phosphate›62.04mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Dasan Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets (10 tablets/PTP x 3) - 30 tablets/PTP
Approval status
Active

MFDS item code 201503176 · Approved 2015.05.27 · Insurance code 678600480

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is one 50/500 mg tablet twice daily; the dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug. 2. Patients receiving metformin: The recommended initial dose of this drug for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. Patients switching to this drug from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
Dasan Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes by administering sitagliptin and metformin together. When used in conjunction with dietary and exercise therapy, it can effectively manage blood sugar levels. This contributes to alleviating diabetes symptoms and preventing complications. Therefore, this medication is used for blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is one 50/500 mg tablet twice daily; the dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug. 2. Patients receiving metformin: The recommended initial dose of this drug for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. Patients switching to this drug from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication is a diabetes treatment that contains sitagliptin and metformin hydrochloride. Firstly, during use of this medication, severe allergic reactions may occur, so if symptoms such as skin rash, urticaria, difficulty breathing, swelling of the face or lips appear, the use should be stopped immediately and a doctor should be consulted. Moreover, pancreatitis, which is inflammation of the pancreas, may rarely occur, so if symptoms such as abdominal pain, vomiting, or loss of appetite appear, medical personnel should be notified immediately. Metformin contained in this medication can cause a rare but serious condition called lactic acidosis, which may be accompanied by symptoms such as muscle pain, weakness, difficulty breathing, abdominal pain, and changes in consciousness, so if these symptoms occur, the hospital should be visited immediately. This medication should not be administered to patients with poor kidney function, severe infections, dehydration, heart failure, or acute myocardial infarction, and it should be temporarily discontinued before and after tests using iodinated contrast agents. Pregnant women or women who may become pregnant and nursing mothers should also refrain from taking this medication. While taking this medication, irregular dietary habits, excessive exercise, and interactions with other medications may lead to hypoglycemia, so caution should be exercised, particularly when used in conjunction with insulin or sulfonylureas, where the risk of hypoglycemia increases, thus monitoring blood sugar levels regularly is important. Additionally, this medication should be administered with caution to patients with liver dysfunction, the elderly, or those with poor nutritional status, and safety should be confirmed through regular kidney function and blood tests. Before and after surgery, the administration of this medication may need to be temporarily halted depending on food intake and kidney function. Finally, it is advisable to avoid alcohol consumption while taking this medication, and in case of overdose, immediate medical attention should be sought for appropriate treatment. Patients taking this medication should be well aware of the precautions mentioned above, and it is crucial to consult medical personnel immediately if any abnormal symptoms occur.

Side effects

anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, peripheral edema, hypoglycemia, severe joint pain often accompanied by disability, pemphigus-like dermatitis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, dermatitis, loss of appetite, weight loss, dyspnea, unstable angina, dizziness, acute renal failure, decreased appetite, gastrointestinal disturbance, itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture, and it is advisable to keep it at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the efficacy of the medication.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3) - 30 tablets/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.